Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN) has become a corporate sponsor of the Global Vitiligo Foundation, which aims to enhance the quality of life for those affected by vitiligo, impacting around 70 million people globally. CEO Bob Moccia emphasized the alignment of this partnership with STRATA's mission to develop innovative treatments for dermatological conditions. The company’s XTRAC excimer laser technology is designed for treating vitiligo and other autoimmune skin diseases, contributing to increased awareness and education concerning available treatment options.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The company's webcast presentation is scheduled for 11:00 AM ET on April 4 and will be accessible via their website. Management will also hold virtual one-on-one meetings throughout the event. STRATA specializes in medical technology for dermatology, offering products like the XTRAC and Pharos excimer lasers for various skin conditions, impacting over 31 million patients in the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) announced its 2021 financial results, showing a 30% revenue increase to $30 million. The fourth quarter revenue hit $9.1 million, a 35% year-over-year growth. Global recurring revenue for 2021 rose to $22.5 million, up 29%. Despite this, they reported a net loss of $2.7 million for the year. The company entered the $5.5 billion acne treatment market via the acquisition of Theraclear. Looking ahead, STRATA expects 2022 revenue between $33 million and $35 million, indicating strong growth despite challenges.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announces that John Bagdasarian has been appointed as Vice President of Professional Relations. His role focuses on strengthening relationships in dermatology and leading the company's participation in dermatological meetings. STRATA will be present at the Annual American Academy of Dermatology Meeting from March 25-29, 2022, in Boston. The company's product portfolio includes advanced laser technologies for treating various skin conditions affecting over 31 million patients in the U.S.

STRATA Skin Sciences (NASDAQ: SSKN) announced it will release its fourth quarter and full year 2021 financial results on March 21, 2022, followed by a conference call at 4:30 p.m. ET. The call will review financial performance and provide corporate updates. STRATA focuses on developing innovative dermatological products, including excimer lasers and treatment systems for conditions like psoriasis and acne, targeting a significant patient base in the U.S.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company focused on dermatologic treatment, will participate in the Oppenheimer 32nd Annual Healthcare Conference. Management is set to present on March 15 at 2:00 pm ET and will engage in one-on-one meetings throughout the day. A live and archived webcast of the presentation will be accessible on the company's investor website. STRATA offers advanced products like the XTRAC excimer lasers and TheraClear system, addressing conditions such as psoriasis and acne, impacting over 31 million patients in the U.S.

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) has appointed Dr. Patricia S. Walker to its Board of Directors, effective February 14, 2022. With over 35 years of experience in dermatology and corporate leadership in medical aesthetics and pharmaceuticals, Dr. Walker's expertise in clinical research and strategic initiatives is expected to enhance STRATA’s operations. Previously, she was the Chief Scientific Officer at Brickell Biotech and has served in key roles at Allergan and Kythera Biopharmaceuticals. Dr. Walker aims to contribute significantly to STRATA’s growth in treating dermatologic conditions and improving patient outcomes.

STRATA Skin Sciences (NASDAQ: SSKN) has launched its next-generation excimer laser system, XTRAC Momentum™ 1.0, in the U.S. The device targets UVB light therapy for skin conditions like psoriasis, atopic dermatitis, and vitiligo. The new system boasts higher power and faster repetition rates, enhancing patient experience. The global treatment market for these conditions surpasses $33 billion, with projected growth. STRATA aims to expand its market footprint with innovative, non-systemic solutions, affirming its commitment to dermatology.

STRATA Skin Sciences has signed an agreement with JuvenIL, a leading distributor in Israel, to market its XTRAC excimer lasers targeting around 300,000 psoriasis and 160,000 vitiligo patients in the country. STRATA’s President & CEO, Robert Moccia, expressed confidence in this partnership as a strategic opportunity to expand into the Israeli market. JuvenIL will leverage its extensive network among over 40 hospitals and 4 Health Maintenance Organizations to commercialize the products effectively.